

ong ong E chang s and Cè ar ng and Th Stock E chang of ong ong tak no spons b tB
for th cont nts of th s annou nt, mak no spons ntat on as to ts accuracB or comp t a ss ande pr ss B
d sc a anB ab tB hatso v r for anB oss ho so v r ar s ng fro or n ane upon th hœ or anB part of th
cont nts of th s annou nt.



溫州康寧醫院股份有限公司 Wenzhou Kangning Hospital Co., Ltd.

(A joint stock limited liability company incorporated in the People's Republic of China)
Stock code: 2120

ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025

1 INTRODUCTION

- 1.1 The board of directors (the “**Board**”) of Wenzhou Kangning Hospital Co., Ltd. (the “**Company**”) is pleased to announce the consolidated annual results of the Company and its subsidiaries (collectively the “**Group**”, “**we**” or “**our**”) for the financial year ended December 31, 2025 (the “**Reporting Period**”) the comparative figures for the previous financial year, i.e. financial year ended December 31, 2024.
- 1.2 The financial statements (the “**Financial Statements**”) of the Group for the reporting period are prepared in accordance with China Accounting Standards for Business Enterprises.

2 FINANCIAL HIGHLIGHTS

2.1 Principal Financial Data and Indicators

	For the year ended December 31,	
	2025 (RMB'000)	2024 (RMB'000)
Revenue	1,619,784	1,654,289
Profit before income tax	69,219	68,099
Income tax expenses	32,615	17,702
Profit	36,604	50,398
Profit attributable to Shareholders of the Company	54,396	65,610
Non-controlling interests	-17,792	-15,212
	As at December 31, 2025 (RMB'000)	As at December 31, 2024 (RMB'000)
Total assets	3,025,567	3,004,953
Total liabilities	1,713,937	1,661,651
Total equity	1,311,630	1,343,302
Equity attributable to Shareholders of the Company	1,187,819	1,223,013
Non-controlling interests	123,811	120,289
	For the year ended December 31,	2024 (RMB'000)
Net cash generated from operating activities	439,970	99,639
Net cash used in investing activities	-203,913	-172,055
Net cash generated from financing activities	-203,584	-76,917
Net increase in cash and cash equivalents	32,442	-149,491

3 BUSINESS REVIEW AND OUTLOOK

3.1 Business Review

In 2025, the continuous geopolitical conflicts around the world and the significant increase in competition and uncertainty of the domestic environment, the domestic medical industry has entered a critical phase in the reform of medical insurance payment as further promoted, the industry competition landscape has continuously been structured, and the social medical service has accelerated to transform into standardization and specialization. Facing the situation that multiple national and international pressures are increasing, the group adhered to the development strategy of "psychiatric healthcare as the foundation and primary healthcare as the strategic growth outlet", targeting quality and efficiency improvement, operational excellence, and stable comprehensive management business development, risk prevention and control and ongoing innovation, and the overall business maintained stable during the reporting period.

During the reporting period, the group recorded total revenue of RMB1,619.8 million, an increase of 2.1% as compared to 2024. Among them, the revenue from operating hospitals amounted to RMB1,448.7 million, an increase of 4.6% as compared to 2024. During the reporting period, the group's net profit attributable to Shareholders of the Company amounted to RMB54.4 million, an increase of 17.1% as compared to 2024. As of December 31, 2025, the group has 34 operating hospitals (December 31, 2024: 32), including an independent stable shared mental hospital (including Echoog Intera Hospital), and the number of operating beds reached 11,508 (December 31, 2024: 11,508).

Psychiatric Healthcare Business

Revenue declined under pressure but overall operation stable and controllable

In 2025, under the combination of multiple factors such as the normalization of medical insurance cost control and the rising labor cost of medical staff, revenue from the group's psychiatric healthcare business has declined as compared to the same period last year, and the profitability of the business is under obvious pressure. However, the increasing demand for psychiatric healthcare, being a mature specialty with operational capabilities and good regional brand advantages, the group actively deepened regional impacts through standardized operation, differentiated positioning, and refined management and cost reduction to enhance the overall operation of the psychiatric healthcare business, and its core fundamentals maintained stability.

3.2 Business Highlights

In 2025, guided by an innovation-driven approach, the Group deepened the coordinated development along various industries, and achieved a number of accomplishments in the fields of digital transformation, discipline construction and scientific research innovation, and industrial upgrading, which further enhanced its core competitiveness, and overall presented a sound development trend of "stable" growth foundation, fostering growth drivers, strengthening barriers and optimizing structure.

In the course of digital transformation, the Group promoted high-quality development through digital empowerment, comprehensive upgrading and generation of hospital Information System electronic medical records and the "theater" and support system, and promoted the "drug traceability code", and launched the pilot application of AI medical records rating and quality control system and medical insurance intelligent supervision system, significantly enhancing the information infrastructure's capabilities in supporting efficient operations and comprehensive management.

In the course of discipline construction and scientific research innovation, the Group was approved for 3 projects under the "Zhangrovne's Top Soldiers (尖兵)", "Leading Geese (领雁)" and "Dedicated Breakthrough Program"; the "cherry's attainment" on difficult practice "dorsal" as selected as the first batch of "small but strong" cultivation and innovation units in Zhangrovne, the 22 national diagnosis and treatment technology/projections were added, 45 SCI papers were published, and 1 international patent was granted throughout the year.

In the course of industrial upgrading, Zhangrovne established Techog Co., Ltd., a subsidiary of the Group, as a listed Zhangrovne Special and Sophisticated Enterprises and a "Leading Enterprises". Meanwhile, Sargstceffence achieved along Zhangrovne Dening Pharmaceutical Co., Ltd. and Zhangrovne Techog Co., Ltd., both being our subsidiaries, and other industrial sectors, gradually building a diversified support system with the pharmaceutical industry, information, psychology services, and forming a "about of industrial mutual promotion of the theater" sector and the industry.

3.3 Business Outlook

The Group's financial position and operating results are mainly subjected to the following risks:

- (i) Risk relating to high reimbursement amount from public medical insurance. From 2023 to 2025, reimbursement amount from public medical insurance accounted for more than 50% of the cash received from sales of goods and rendering of service for the respective Bars. If the Group's healthcare facilities are unable to maintain the of designated medical insurance institutions in the future, or there are adverse changes on the national public medical insurance policy in respect of treatment of certain diseases and general diseases, the Group's operating results will be affected adversely.
- (ii) Risk relating to shortage of professional medical talents. Under the laws and regulations of the PRC, healthcare facilities shall maintain a certain number of medical staff. With the increase in the number of healthcare facilities of the Group, we are unable to recruit or maintain adequate medical staff, especially face difficulties to provide patients with the desired medical services, which in turn adversely affect our operating results; and
- (iii) Risk relating to failure to obtain qualifications and licenses required for our operations. Healthcare facilities are required to obtain the medical practice licenses for carrying out their businesses, which usually has a valid period and requires regular inspections by the regulator/authorities. If the healthcare facilities of the Group are unable to obtain the licenses in the future due to poor management or non-compliant operation, our operating results will be affected adversely.

Prospect

In 2026, although the uncertain factors in the global economy and normal development of domestic medical insurance and related industry competition continue to exist, the continuous change of public health affairs and the constant development of population aging in China are a foundation for the long-term growth and the prospect of healthcare and related businesses. Meanwhile, the development of social healthcare is obvious, leading to higher standards, competition, and brand concentration. Being the first Bar of the "15th Five-Year Plan", 2026 is an important Bar for the Group's transformation and development strategy, and the Group adheres to the general principle of "seeking progress while maintaining stability" and making breakthroughs in innovation, and accelerating the transformation of its development model from scale expansion to connotation improvement and efficient operation. The Group continues to uphold the core values of "being sincere and serving the human touch", staying true to the essence of healthcare services, and pursuing the development of "Specialization and Innovation, Quality Improvement and Efficiency Enhancement". Being a leading enterprise in general practice operations, the Group sees the development opportunities arising from the trends of specialization and related healthcare, and further strengthens its position as a medical practice with better and more healthcare services to create long-term stable value for shareholders.

4 MANAGEMENT DISCUSSION AND ANALYSIS

4.1 Financial Review

The group recorded revenue of ₱ B1,619.8 million during the reporting period, representing a decrease of 2.1% from ₱ B1,654.0 million in 2024, of which revenue from the operation of our hospitals amounted to ₱ B1,448.7 million, representing a decrease of 4.6% from ₱ B1,514.0 million in 2024. During the reporting period, the gross profit margin of our hospitals was 25.8% (2024: 25.9%), and the group's overall gross profit decreased to ₱ B419.1 million, representing a decrease of 4.4% from ₱ B438.0 million in 2024. Net profit attributable to Shareholders of the Company for the reporting period was ₱ B54.4 million, representing a decrease of 17.1% from ₱ B65.0 million in 2024. During the reporting period, the group's net cash generated from operating activities was ₱ B440.0 million (2024: ₱ B99.6 million), representing an increase of ₱ B340.3 million from 2024.

4.1.1 Revenue and Cost of Revenue

The group generates revenue mainly through the following three areas: (i) revenue from operating hospitals; (ii) revenue from other health care related businesses; and (iii) other revenue not related to health care businesses.

The table below sets forth a breakdown of total revenue for the periods indicated:

	For the year ended December 31,	
	2025	2024
	(RMB'000)	(RMB'000)
Revenue from operating owned hospitals	1,448,706	1,517,773
Including: revenue from psychiatric healthcare business	1,019,941	1,055,907
Revenue from medical healthcare business	428,765	461,866
Revenue from other healthcare related business	168,501	135,921
Other revenue not related to healthcare business	2,577	595
Total revenue	<u>1,619,784</u>	<u>1,654,289</u>

Revenue and cost of revenue from operating owned hospitals

Revenue from operating owned hospitals consists of fees ("Billing Revenue") charged for outpatient visits and inpatient services at the Group's various hospitals, which can be divided into treatment and general healthcare services and pharmaceutical sales, as well as variable considerations for medical services provided by the Group, mainly including medical insurance settlement fees.

The table below sets forth a breakdown of the Billing Revenue of the Group's owned hospitals attributed to operating revenue by psychiatric healthcare business and medical healthcare business for the periods indicated:

	For the year ended December 31,	
	2025	2024
	(RMB'000)	(RMB'000)

Billing Revenue from revenue for the periods indicated: (0)1 T f0.0T0.053 Td(002)0.5 (ps

During the reporting period, the Group's total hospital billing revenue amounted to RMB1,479.0 million, representing a decrease of 6.5% from 2024, primarily due to the decrease in inpatient days. The decrease in average outpatient spending per visit and average inpatient spending per day contributed. During the reporting period, the variable cost ratio was RMB30.3 million, representing a decrease of RMB34.0 million from 2024, and the variable cost ratio as a percentage of billing revenue decreased to 2.1% (2024: 4.1%).

The table sets forth a breakdown of the billing revenue, cost of revenue and gross profit of the Group's total hospital business by psychiatric business and elderly healthcare business for the periods indicated:

	For the year ended	
	December 31,	
	2025	2024
	(RMB'000)	(RMB'000)
Billing Revenue from psychiatric healthcare business	1,047,554	1,107,269
Cost of revenue	712,285	745,959
Gross profit	335,269	361,310
Billing Revenue from elderly healthcare business	431,473	474,785
Cost of revenue	362,640	379,458
Gross profit	68,833	95,327

During the reporting period, the total hospital revenue of the Group amounted to RMB1,479.0 million, representing a decrease of RMB103.0 million from 2024, mainly due to the decrease in billing revenue of inpatient days, emergency department, long-term nursing hospital, Bang Change nursing hospital and nursing hospital. During the reporting period, the gross profit of the Group's total hospital business as a percentage of billing revenue has decreased by 11.5% as compared with that in 2024, mainly due to the decrease in inpatient spending per day.

The table below sets forth a breakdown of Billing Revenue of the Group's owned hospitals by inpatient and outpatient beds. Each attribute characterizes business and derived character business for the period and category, the relevant operating data:

Psychiatric healthcare business

	For the year ended December 31,	
	2025	2024
Inpatients		
Inpatient beds at period end	8,708	8,928
Effective inpatient service bed-days capacity utilization rate (%)	3,178,420	3,267,648
Number of inpatient bed-days	91.4	88.4
Total inpatient and general hospital revenue service attributable to inpatients (in RMB'000)	2,904,367	2,889,163
Average inpatient spending per bed-day on total inpatient and general hospital services (in RMB)	791,185	844,076
Average inpatient spending per bed-day on hospital pharmaceuticals attributable to inpatients (in RMB'000)	272	292
Average inpatient spending per bed-day on pharmaceuticals (in RMB)	87,657	89,656
Total inpatient revenue (RMB'000)	878,842	933,732
Total average inpatient spending per bed-day (RMB)	303	323
Outpatients		
Number of outpatient visits	657,802	474,581
Total outpatient and general hospital revenue service attributable to outpatients (in RMB'000)	43,256	45,078
Average outpatient spending per visit on total outpatient and general hospital services (in RMB)	66	95
Average outpatient spending per visit on hospital pharmaceuticals attributable to outpatients (in RMB'000)	125,456	128,459
Average outpatient spending per visit on pharmaceuticals (in RMB)	191	271
Total outpatient revenue (RMB'000)	168,712	173,537
Total average outpatient spending per visit (RMB)	257	366

**For the year ended
December 31,
2025** 2024

Total treatment and general healthcare services revenue (RMB'000)	834,441	889,154
Total pharmaceutical sales revenue (RMB'000)	213,113	218,115

During the reporting period, inpatient BCG revenue from the psychiatric business as RMB78.8 million, representing a decrease of 5.9% from 2024, mainly due to the decline in the growth rate of inpatient hospitalization, including long-term hospitalization, temporary hospitalization, day care hospitalization and ambulatory hospitalization, and the resulting decrease in spending per bed per day of the psychiatric hospital business by 6.2% as compared with the same period in 2024. Inpatient BCG revenue of the psychiatric hospital business accounted for 83.9% (2024: 84.3%) of the BCG revenue of the psychiatric hospital business.

During the reporting period, outpatient BCG revenue from the psychiatric hospital business

Elderly healthcare business

	For the year ended December 31,	
	2025	2024
Inpatients		
Inpatient beds at period end	2,800	2,580
Effective inpatient service bed-days	1,022,000	944,280
Occupancy rate (%)	89.6	96.1
Number of inpatient bed-days	916,061	907,255
Treatment and general healthcare services revenue attributable to inpatients (RMB'000)	316,454	346,074
Average inpatient spending per visit on treatment and general healthcare services (RMB)	346	382
Pharmaceutical sales revenue attributable to inpatients (RMB'000)	92,910	93,599
Average inpatient spending per bed-day on pharmaceutical sales (RMB)	101	103
Total inpatient revenue (RMB'000)	409,364	439,673
Total average inpatient spending per bed-day (RMB)	447	485
Outpatients		
Number of outpatient visits	62,353	83,661
Treatment and general healthcare services revenue attributable to outpatients (RMB'000)	9,812	15,632
Average outpatient spending per visit on treatment and general healthcare services (RMB)	157	187
Pharmaceutical sales revenue attributable to outpatients (RMB'000)	12,297	19,480
Average outpatient spending per visit on pharmaceutical sales (RMB)	197	233
Total outpatient revenue (RMB'000)	22,109	35,112
Total average outpatient spending per visit (RMB)	355	420
Total treatment and general healthcare services revenue (RMB'000)	326,266	361,706
Total pharmaceutical sales revenue (RMB'000)	105,207	113,079

During the reporting period, inpatient B n g ' a e n a from the d r B h a thear bus n s s amount d to RMB409.4 million, e p r e s e n t n g a d e r a s of 6.9% as compared to 2024, a n B d a to a d e r a s of 7.8% n a e r a g n p a e n t s p e n d n g p e r b e d p e r d a n e s p e c t of the d r B h a thear bus n s s at the e r a t r c s o s p t a c o m p a r e d to 2024 d a to a d u s t a m e n t s of bus n s s s t r u c t u r e . I n p a e n t B n g ' a e n a from the d r B h a thear bus n s s account d for 94.9% (2024: 92.6%) of the B n g ' a e n a from the d r B h a thear bus n s s.

During the reporting period, outpatient B n g ' a e n a from the d r B h a thear bus n s s amount d to RMB22.1 million, e p r e s e n t n g a d e r a s of 37.0% as compared to 2024, p r o p o r t i o n B d a to the d e r a s of 25.5% n t h n u m b e r of o u t p a e n t v i s i t s and the d e r a s of 15.5% n t h a e r a g n o u t p a e n t s p e n d n g p e r v i s i t e s u e d from the d e c a n d o u t p a e n t bus n s s of n g B a n g C h a n g e n g n n g o s p t a . O u t p a e n t B n g ' a e n a from the d r B h a thear bus n s s account d for 5.1% (2024: 7.4%) of the B n g ' a e n a from the d r B h a thear bus n s s.

During the reporting period, as the inpatient and outpatient e g e n t u n d e r the d r B h a thear bus n s s both d e c a n d , B n g ' a e n a from the a t a m e n t s and g e n e r a l h a thear e r v e s u n d e r the g r a t r c h a thear bus n s s d e r a s d b y 9.8% from 2024, t h e s p r o p o r t i o n to the B n g ' a e n a from the d r B h a thear bus n s s of o n d h o s p i t a l s d e r a s d to 75.6% (2024: 76.2%), and the B n g ' a e n a from the p h a r m a e u t c a s e s u n d e r the d r B h a thear bus n s s d e r a s d b y 7.0% as compared to 2024, account ng for 24.4% (2024: 23.8%) of the B n g ' a e n a from the d r B h a thear bus n s s. I n p a r t i c u l a r , the p r o p o r t i o n of i n p a e n t B n g ' a e n a from the p h a r m a e u t c a s e s to the t o t a l i n p a e n t B n g ' a e n a from the d r B h a thear bus n s s n e e a s d to 22.7% (2024: 21.3%), and the p r o p o r t i o n of o u t p a e n t B n g ' a e n a from the p h a r m a e u t c a s e s to the t o t a l o u t p a e n t B n g ' a e n a from the d r B h a thear bus n s s n e e a s d to 55.6% (2024: 55.5%).

Cost of e e n a of the g r o u p ' s o n d h o s p i t a l s p r o p o r t i o n c o n s i s t s of p h a r m a e u t c a s e s and c o n s u m a b l e s u s e d u p o n e b e n e f i t s a n d e p e n s e s , d e p r e c i a t i o n a n d a m o r t a t i o n of o n g o i n g a s s e t s , c a n t e n e p e n s e s a n d e s t a n d i n g f e e s . T h e t a b l e b e l o w s e t s f o r t h a b r e a k d o w n of c o s t of e e n a of the g r o u p ' s o n d h o s p i t a l s for the p e r i o d s e n d e d :

	For the year ended December 31,	
	2025	2024
	(RMB'000)	(RMB'000)
Pharmaceuticals and consumables used	300,340	340,120
Equipment benefits and pensions	472,192	464,874
Depreciation and amortization of ongoing assets	105,477	127,032
Canteen pensions	67,903	68,571
Testing fees	10,700	16,112
Others	118,313	108,708
Cost of revenue of owned hospitals	1,074,925	1,125,417

During the reporting period, the cost of revenue of the group's owned hospitals

	For the year ended December 31,	
	2025	2024
Ordinary hospital business	25.8%	25.9%
Specialty hospital business	30.2%	29.4%
Other hospital business	15.4%	17.8%
Other business	26.5%	33.7%
Consolidated gross profit margin	<u>25.9%</u>	<u>26.5%</u>

During the reporting period, consolidated gross profit margin of the group decreased to 25.9% (2024: 26.5%).

4.1.3 Tax and Surcharge

During the reporting period, the tax and surcharge of the group amounted to RMB11.2 million (2024: RMB12.3 million), of which hospital property tax of RMB8.1 million and property tax of RMB8.1 million.

4.1.4 Selling Expenses

During the reporting period, the selling expenses of the group amounted to RMB7.7 million (2024: RMB10.0 million), mainly representing promotional expenses relating to pharmaceutical companies, inpatient hospital and other non-ordinary hospital. The proportion of selling expenses to the revenue from operating ordinary hospital of the group was 0.5% (2024: 0.7%).

4.1.5 Administrative Expenses

During the reporting period, administrative expenses of the group primarily consist of employee benefits and expenses, depreciation and amortization, consumption expenses, travel expenses and other expenses. The table below sets forth a breakdown of administrative expenses of the group for the periods indicated:

	For the year ended December 31,	
	2025	2024
	(RMB'000)	(RMB'000)
Employee benefits and expenses	140,740	133,002
Depreciation and amortization	31,379	30,792
Consumption expenses	9,423	9,037
Travel expenses	4,661	4,978
Others	46,903	49,537
Total administrative expenses	<u>233,106</u>	<u>227,346</u>

During the reporting period, the administrative expenses of the group amounted to RMB233.1 million, representing an increase of 2.5% as compared with 2024, which was mainly due to an increase in employee benefits and expenses of 5.8% as compared with 2024. The proportion of the administrative expenses to the revenue from operating ordinary hospital of the group was 16.1% (2024: 15.0%).

4.1.6 Research and Development Expenses

During the reporting period, the Group's research and development expenses mainly consisted of contract research, development of information software and construction of Internet hospital platform. The table below sets forth the breakdown of the Group's research and development expenses for the periods indicated:

	For the year ended December 31,	
	2025 (RMB'000)	2024 (RMB'000)
Contract research	23,313	25,088
Development of information software	5,339	9,827
Construction of Internet hospital platform	1,472	1,604
Total	30,124	36,519

During the reporting period, the Group's research and development expenses amounted to RMB30.1 million (2024: RMB36.5 million), representing a decrease of 17.5% as compared with 2024. The proportion of research and development expenses to the revenue from operating ordinary hospitals of the Group decreased to 2.1% (2024: 2.4%).

4.1.7 Finance Expenses – Net

Our finance income included net income from bank deposits, and the finance expense included bank borrowing net expense, net expense on lease assets and net expense on finance leases. The table below sets forth the breakdown of our finance expense for the periods indicated:

	For the year ended December 31,	
	2025 (RMB'000)	2024 (RMB'000)
Interest income	-842	-3,123
Foreign exchange losses	30	157
Bank borrowing net expense	27,289	33,143
Interest expense on lease assets	11,522	8,458
Interest expense on finance leases	6,942	7,900
Others	1,315	1,058
Finance expenses – net	46,256	47,593

During the reporting period, the net finance expense of the Group amounted to RMB46.3 million, representing a decrease of RMB1.3 million as compared with 2024, among which bank borrowing net expense decreased by RMB5.9 million as compared with 2024, mainly due to lower net interest rates of bank borrowing of the Group.

4.1.8 Investment Gains

Our net investment gains consist of the share of net investment losses/gains accounted for under the equity method and gains on disposal of long-term investments and net investment gains in the management products. The table sets forth the breakdown of our net investment gains for the periods indicated:

	For the year ended	
	December 31,	
	2025	2024
	(RMB'000)	(¥ B'000)
Share of net investment losses/gains accounted for under the equity method	-1,464	-1,089
Gains on disposal of long-term investments	4,804	1,844
Net investment gains in the management products	12	.
	3,352	755

4.1.11 Non-Operating Income and Non-Operating Expenses

Our non-operating income mainly consists of government grants and donations received, and our non-operating expenses mainly consist of losses on scrapping of non-current assets, donation expenses, and expenses on medical supplies. The table below sets forth the breakdown of our non-operating income and non-operating expenses for the periods indicated:

	For the year ended	
	December 31,	
	2025	2024
	(RMB'000)	(¥ B'000)
Government grants	-	86
Donations received	267	47
Other non-operating income	1,054	1,396
Non-operating income	1,321	1,529
Losses on scrapping of non-current assets	1,373	1,117
Donation expenses	3,070	2,698
Expenses on medical supplies	1,191	2,669
Other non-operating expenses	11,303	2,299
Non-operating expenses	16,937	8,783

During the reporting period, the non-operating income of the Group amounted to ¥11.3 million, representing an increase of ¥0.2 million as compared to 2024. During the reporting period, the non-operating expenses of the Group increased to ¥16.9 million as compared to 2024, mainly due to the increase of ¥1.5 million on expenses on medical supplies as compared to 2024 and the increase of ¥9.0 million on other non-operating expenses as compared to 2024.

4.1.12 Income Tax Expense

During the reporting period, income tax expense amounted to ¥32.6 million (2024: ¥17.7 million), representing an increase of 84.3% as compared to 2024. The increase is mainly due to the fact that deferred tax assets were utilized to offset losses or were reversed upon maturity. In 2025 and 2024, our effective tax rates were 47.1% and 26.0%, respectively.

4.2 Financial Position

4.2.1 Inventory

As of December 31, 2025, the balance of inventory amounted to \$ B46.0 million (as of December 31, 2024: \$ B50.6 million), and including the related inventory and turnover ratios.

4.2.2 Accounts Receivable

As of December 31, 2025, the balance of accounts receivable amounted to \$ B462.9 million (as of December 31, 2024: \$ B571.8 million), representing a decrease of 19.0% as compared with the balance as of December 31, 2024, and attributable to the decrease in the amount recorded in the related financial accounts as a result of the decrease in the present amount due to the change in present rates of the related cash flows. The change in present rates of the related cash flows is 0.02.

4.2.7 Construction in Progress

As of December 31, 2025, the balance of construction in progress amounted to ₹ 13.1 million (as of December 31, 2024: ₹ 185.2 million). The decrease in construction in progress is mainly due to the transfer upon completion of the construction projects of such long-term assets and long-term engineering assets.

4.2.8 Right-of-use Assets

As of December 31, 2025, right-of-use assets were ₹ 192.4 million (as of December 31, 2024: ₹ 161.8 million).

4.2.9 Intangible Assets

As of December 31, 2025, intangible assets were ₹ 285.8 million (as of December 31, 2024: ₹ 291.5 million).

4.2.10 Goodwill

As of December 31, 2025, goodwill was ₹ 126.5 million (as of December 31, 2024: ₹ 114.2 million).

4.2.11 Long-term Prepaid Expenses

As of December 31, 2025, long-term prepaid expenses were ₹ 121.6 million (as of December 31, 2024: ₹ 150.4 million), mainly attributable to the depreciation expenses of ₹ 9.7 million and the amortization of decoration costs of ₹ 38.0 million during the reporting period.

4.2.12 Deferred Tax Assets

As of December 31, 2025, deferred tax assets were ₹ 55.3 million (as of December 31, 2024: ₹ 56.2 million).

4.2.13 Accounts Payable

As of December 31, 2025, accounts payable were ₹ 160.8 million (as of December 31, 2024: ₹ 131.9 million).

4.2.14 Receipts in Advance

As of December 31, 2025, receipts in advance and contract liabilities not ascribed to RMB23.3 million (as of December 31, 2024: RMB21.3 million).

4.2.15 Other Payables

As of December 31, 2025, other payables not ascribed to RMB91.9 million (as of December 31, 2024: RMB81.3 million).

4.3 Liquidity and Capital Resources

The table below sets forth the information as extracted from the consolidated cash flow statements of the Group for the periods indicated:

	For the year ended	
	December 31,	
	2025	2024
	(RMB'000)	(RMB'000)
Net cash generated from operating activities	439,970	99,639
Net cash used in investing activities	-203,913	-172,055
Net cash generated from financing activities	-203,584	-76,917
Net increase in cash and cash equivalents	<u>32,442</u>	<u>-149,491</u>

4.3.1 Net Cash Generated from Operating Activities

During the reporting period, net cash generated from operating activities amounted to RMB440.0 million, primarily consisting of net profit attributable to the parent company of RMB54.4 million, adjustments of RMB32.0 million for credit impairment losses and asset impairment losses and adjustment of RMB160.8 million for depreciation and amortization of various assets. The cash inflow from change in working capital amounted to RMB165.0 million mainly due to the decrease in accounts receivable balances.

4.3.2 Net Cash Used in Investing Activities

During the reporting period, net cash used in investing activities amounted to RMB203.9 million, primarily due to the amount of RMB189.5 million for purchasing property, plant and equipment, net of depreciation, among others, the investments in the infrastructure of long-term operating assets, such as long-term operating assets and non-current operating assets.

4.3.3 Net Cash Generated from Financing Activities

During the reporting period, net cash generated from financing activities amounted to RMB-203.6 million, of which the cash outflow from dividends distributed to shareholders as RMB34.5 million and the cash outflow from share repurchases used for cancellation as RMB22.4 million.

4.4.4 Lease Liabilities

The lease liabilities of the Group prior to 2025 consist of operating lease arrangements. As of December 31, 2025, the present value of unsettled lease payments under non-cancellable lease arrangements, after deducting an amount of ₹ B36.4 million which is due thereon prior, as ₹ B148.5 million.

4.4.5 Financial Instruments

Financial instruments of the Group consist of accounts receivable, other non-current financial assets, other receivables, cash and cash equivalents, bank borrowings, accounts payable and other payables. The Company's management manages and monitors the risks to ensure effective measures are implemented in a timely manner.

4.4.6 Exposure to Fluctuation in Exchange Rates

The Group's deposits in foreign currencies, which mainly involve risks of fluctuation in the exchange rate of INR against USD. The Group is therefore exposed to foreign exchange risks.

As of December 31, 2025, the Group did not use derivative financial instruments to hedge against the potential exchange rate risk. The management of the Company manages the exchange rate risk by monitoring the movement of foreign currency exchange rates, and considers hedging against significant foreign currency exposures should such arise.

4.4.7 Gearing Ratio

As of December 31, 2025, the Group's gearing ratio (total liabilities divided by total assets) increased to 56.6% (as of December 31, 2024: 55.3%).

4.4.8 Employees and Remuneration Policy

As of December 31, 2025, the Group had a total of 5,354 full-time employees (as of December 31, 2024: 4,869 full-time employees). During the reporting period, employees' remuneration (including salaries and other forms of employee benefits) amounted to approximately ₹ B659.8 million (2024: ₹ B644.1 million). The average remuneration of our employees amounted to ₹ B126.9 thousand per year (including pension, social insurance scheme and housing provident fund scheme borne by the Group). Remuneration of employees is determined with reference to the salary level in the same industry and the qualifications, experience and performance of such employees.

4.4.8.1 **Equity Incentive Scheme**

In order to further motivate the employees and management and other key persons of the group, the Company has formulated the Equity Incentive Scheme for the year 2018 of Wipro Engineering Solutions Co., Ltd. (the **Equity Incentive Scheme**), which was considered and approved at the annual general meeting of the Company for the year 2017 convened on June 13, 2018. In order to meet the requirement of ascertained share capital for the Company's A share listing application in the future, the Board of the Company considered and approved the

4.4.8.2 Share Award and Trust Scheme

To attract, motivate and retain the best and the needed core backbone members of the channels and management to continuous strive for the continuous operation and development of the Company in the future, in accordance with the requirements of the Company and of the people's Republic of China and other relevant laws, administrative regulations, regulatory documents and the Articles of Association, the Company has formulated the Share Award and Trust Scheme, which has considered and approved by the 2023 first extraordinary general meeting of the Company convened on September 27, 2023. The essence of the content of the scheme, capital deduction used for share award has the same meanings as those defined in the circular of the Company dated September 8, 2023 and the announcement of the Company dated September 27, 2023, April 12, 2024, April 23, 2024 and June 18, 2024.

Pursuant to the Share Award and Trust Scheme, a trust deed has been entered into between the Company and the trustee. The trust has been constituted to serve the Share Award and Trust Scheme. The trustee shall assist the administrative of the Share Award and Trust Scheme and shall, subject to the relevant provisions of the trust deed and upon the instruction of the Company, acquire Shares through on-market transactions and such Shares shall be acquired by the trust through the funds transferred by the Company and shall be transferred and disposed of by the trustee at the Company's instructions. Such Shares under the Share Award and Trust Scheme shall not account for more than 5% (being 3,730,015 shares) of the total share capital of the Company following the date on which the mandate of the Share Award and Trust Scheme is granted or at the date on which the approval of updating the limit is obtained. The awards granted to the selected participants shall be held by the trustee for the benefit of the selected participants, and the trustee shall, for the purposes of vesting of the awards and upon the instruction of the Board and/or its delegates, release from the trust the award shares to the selected participants or sell the award shares so vested through on-market transactions at the prevailing market price and pay the selected participants the proceeds from such sale in accordance with the terms of the Share Award and Trust Scheme and relevant provisions under the trust deed.

Under the Share Award and Trust Scheme, the selected participants (including consolidated persons) of the first actual grant comprised a total of 36 persons, the 364,100 award shares being granted. The selected participants (including consolidated persons) of the second phase of the actual grant comprised a total of 36 persons, the 616,000 new shares being granted. The selected participants (including consolidated persons) of the third phase of the actual grant comprised a total of 52 persons, the 335,000 award shares being granted. As of the date of this announcement, a total of 10 participants held, corresponding to a total of 92,000 award shares. As of the date of this announcement, the selected participants of the actual grant under the Share Award and Trust Scheme comprised 98 persons, and a total of 1,240,100 award shares had been granted, and 12,750 shares had been forfeited. The award shares granted accounted for approximately 1.7615% of the total issued share capital of the Company including the Shares purchased but not yet cancelled by the Company as of the date of this announcement. For details of the grant plan, please refer to the circular of the Company dated September 8, 2023 and the announcement of the Company dated September 27, 2023, April 12, 2024, April 23, 2024 and June 18, 2024.

5 SIGNIFICANT EVENTS

5.1 Proposed Final Dividend

The Board has recommended the payment of a proposed Final Dividend. Based on the total share capital excluding the Shares purchased but not yet cancelled by the Company for the record date determined by the independent auditor of the proposed distribution of profit for the year 2025 (as of the date of this announcement, the Company's total share capital is 72,358,900 Shares. After deducting 1,959,800 Shares purchased but not yet cancelled by the Company, the total issued share capital amounted to 70,399,100 shares), a Shareholder is to be paid a cash dividend of RMB3.2 (inclusive of tax) per 10 Shares of the Company, the total proposed cash dividend amounting to RMB22,527,712 (inclusive of tax), representing 41.4% of the net profit attributable to shareholders of the parent company as set out in the consolidated statement of accounts for the reporting period (the total amount of net dividend and proposed Final Dividend for 2025 is RMB35,271,550, representing 64.8% of the net profit attributable to shareholders of the parent company as set out in the consolidated statement of accounts for the reporting period). The proposed Final Dividend is denominated and declared in RMB, payable in RMB to holders of Domestic Shares and in USD to holders of Shares. The exchange rate for the proposed Final Dividend payable in USD is the average of the benchmark exchange rates of USD against RMB as announced by the People's Bank of China for the five business days prior to the date of declaration of the proposed Final Dividend (i.e. the date of the annual general meeting of the Company). The proposed distribution of profit for the year 2025 is subject to the consolidated resolution and approval of the Company at the AGM of the Company.

Subject to the approval of the proposed Final Dividend by the Shareholders at the forthcoming AGM, it is expected that the payment date of the proposed Final Dividend will be no later than July 8, 2026. The Company will announce in due course the date of the AGM and the terms of the closure of the register of members of the Shares for the purpose of determining the list of Shareholders entitled to attend and vote at the AGM and to qualify for the proposed Final Dividend.

Pursuant to the Enterprise Income Tax Law of the People's Republic of China and its implementing regulations, which came into effect on January 1, 2008, the Company is required to withhold and pay on behalf of the Shareholders of non-resident enterprises whose names appear on the register of members of the Company's H-share holders the enterprise income tax at a rate of 10% on the distribution of cash dividends. Any Shares registered in the name of non-individual Shareholders (including in the name of Hong Kong Special Administrative Region Company (collective) and, otherwise, agents or trustees or other organizations or bodies) are regarded as Shares held by non-resident enterprise Shareholders. According to the dividends payable to such Shareholders are subject to withholding corporate income tax. If Shareholders wish to change their status as Shareholders, please contact the nominee or trustee for the relevant procedures. The Company will withhold corporate income tax on behalf of the relevant Shareholders whose names appear on the register of members of the Shares on the record date in strict accordance with the law or as required by the relevant government authorities.

If the individual holders of Shares are residents of Hong Kong or places or residents of countries which have entered into the relevant tax agreement with the ROC in respect of the distribution of cash dividends to the extent that the Company shall be deemed to be a resident of the relevant country for the purposes of the relevant tax agreement. If an individual holder of Shares is a resident of a country which has entered into a tax agreement with the ROC at a tax rate over 10% on dividends, the Company shall be deemed to be a resident of the relevant country for the purposes of the relevant tax agreement. In such cases, if the relevant individual holder of Shares wishes to apply for a refund of the excess tax withheld as a result of the application of the 10% tax rate, the Company shall process the application on behalf of the relevant individual holder in accordance with the relevant pre-emptive tax agreement, provided that the relevant Shareholder submits to Computershare Hong Kong Investor Services Ltd the supporting information as required by the note of the tax agreement. Upon approval by the competent tax authorities, the Company shall assist in refunding the excess tax withheld. If an individual holder of Shares is a resident of a country which has entered into a tax agreement with the ROC that a dividend tax rate higher than 10% but not over 20%, the Company shall withhold and pay on behalf of the individual holder the tax at the effective tax rate under the relevant tax agreement. If the individual holder of Shares is a resident of a country that has entered into a tax agreement with the ROC that a dividend tax rate of 20%, or a resident of a country in which the ROC has not entered into any tax agreement, or otherwise, the Company shall withhold and pay personally on behalf of the individual holder at the rate of 20%.

As of December 31, 2025, no Shareholders have applied or agreed to apply for dividends.

6 PURCHASE, SALE OR REDEMPTION OF LISTED SECURITIES

During the reporting period, the Share repurchases could have not as a net asset value per Share and/or earnings per Share, which are the interests of the Company and the Shareholders as a whole, the Company repurchased a total of 2,270,900 Shares for an aggregate consideration of USD24,515,933.18 on the Hong Kong Stock Exchange (the "Repurchased Shares"). Details of the repurchased Shares are as follows:

Repurchase month	Number of Repurchased Shares	Price paid per Share		Total consideration Share (i)
		Highest	Lowest	

7 REVIEW OF ANNUAL RESULTS

The Audit Committee consists of two independent non-executive Directors, i.e. Zou Wentang (the chair of the Audit Committee) and Mr. Jiang, and one non-executive Director, i.e. Mr. Changhao. Among them, Mr. Zou Wentang has the appropriate professional qualification (a Chartered Certified public accountant accredited by the Chartered Institute of Certified Accountants).

The Audit Committee has reviewed the Group's annual results for the financial year ended December 31, 2025 and opined that applicable accounting standards and accounting policies have been complied with and that adjusted disclosures have been made by the Company.

8 COMPLIANCE WITH CG CODE

During the reporting period and up to the date of this announcement, the Company has complied with all applicable provisions in the Code.

9 COMPLIANCE WITH THE MODEL CODE

The Company has adopted the Model Code as a code of conduct of the Company for its Directors' and Supervisors' securities transactions in the Company. Having read specifically in the Company's Code of Conduct, the Directors and the Supervisors of the Company have complied with the requirements set out in the Model Code during the reporting period.

10 EVENTS AFTER THE REPORTING PERIOD

Refer to the announcements of the Company dated February 5, 2026 and March 2, 2026 (the "Announcements"), in respect of which, to the best of the knowledge, information and belief of the Board of the Company, the public float of the Company is approximately 24.11%, which falls below the requirements of Rule 8.08 and Rule 19A.28B of the Listing Rules that at least 25% (the "Minimum Prescribed Percentage") of the total issued shares of the Company must be held by the public.

As stated in the Announcements, the Company has submitted an application to the CSRC as at August 21, 2025 in respect of the conversion of 9,286,359 domestic Shares into Shares of the Company upon completion of the full redemption of Shares, the Company will then announce the results.

The Company continues to monitor the issue of insufficient public float and will make monthly announcements in accordance with the Listing Rules to keep Shareholders and the market informed of the progress and restoring the public float.

In addition to the above, there are no significant subsequent events occurred to the Group since the end of the reporting period to the date of this announcement.

11 AUDITORS AND WORKING SCOPE

The consolidated financial statements of the Group for 2025, which have been prepared in accordance with Chinese Accounting Standards for Business Enterprises have been audited by BDO, who has issued a standard audit report with unqualified opinions on the consolidated financial statements.

According to the Note on Structure Element of the Accounting Standards for

Items	For the year ended	
	December 31, 2025	2024
Taxes and surcharges	11,246,125	12,336,886
12,336,886 distributed expenses		

For the year ended
December 31,
2025

2024

Items

VI. Other comprehensive income, net of tax

Other comprehensive income attributable to
shareholders of the parent company, net of tax

(I) Other comprehensive income that cannot be
classified to profit and loss

1. Changes arising from the assessment of
defined benefit plan -
2. Other comprehensive income that cannot be
classified to profit or loss under the equity method -
3. Change in fair value of other equity
instrument investments -
4. Change in fair value due to the net present
value of risk -

(II) Other comprehensive income that can be classified to
profit and loss

1. Other comprehensive income that can be classified to
profit or loss under the equity method -
2. Change in fair value of other debt investments -
3. Amount of financial assets classified into other
comprehensive income -
4. Credit impairment provisions for other debt investments -
5. Gains for cash flow hedges -
6. Exchange difference on translation of financial
statements in foreign currencies -
7. Others -

Other comprehensive income attributable to
non-controlling interests, net of tax -

VII. Total comprehensive income

Attributable to shareholders of the parent company
Attributable to non-controlling interests

36,603,923	50,397,711
54,395,980	65,610,189
-17,792,057	-15,212,477

VIII. Earnings per Share:

(I) Basic Earnings per Share (Basic EPS)
(II) Diluted Earnings per Share (Diluted EPS)

0.76	0.88
0.76	0.88

12.2.2 Annual Consolidated Balance Sheets

(Amounts in Billions of Dollars)

December 31, 2013

ASSETS	December 31, 2025	December 31, 2024
Due on operations	-	-
Goodwill	126,454,938	114,158,434
Intangible assets	121,609,291	150,407,031
Deferred tax assets	55,346,816	56,197,545
Other non-current assets	15,514,861	11,233,664
Total non-current assets	<u>2,093,531,524</u>	<u>2,010,231,682</u>
TOTAL ASSETS	<u>3,025,567,371</u>	<u>3,004,953,161</u>
LIABILITIES AND SHAREHOLDERS' EQUITY	December 31, 2025	December 31, 2024
Current liabilities:		
Short-term borrowings	109,243,677	91,000,000
Borrowings from central bank	-	-
Accounts from banks and other financial institutions	-	-
Financial assets held for trading	1,805,503	14,000,000
Derivative financial assets	-	-
Accounts payable	160,803,092	131,936,380
Deposits advanced	23,327,087	21,319,198
Contract assets	161,105	49,771
Financial assets sold under repurchase agreements	-	-
Deposit of deposits and deposits from other banks	-	-
Funds received as agent of stock exchange	-	-
Funds received as stock under offer	-	-
Employee benefits payable	84,431,493	85,747,297
Taxes payable	35,809,004	39,128,084
Other payables	91,859,119	81,287,433
Fees and commissions payable	-	-
Insurance accounts payable	-	-
Assets held for sale	-	-
Non-current assets held for sale	201,407,510	229,270,444
Other current assets	3,214,867	615,218
Total current liabilities	<u>712,062,458</u>	<u>694,353,825</u>

LIABILITIES AND SHAREHOLDERS' EQUITY	December 31, 2025	December 31, 2024
Non-current liabilities:		
Provisions for insurance contracts	-	-
Long-term borrowings	746,952,957	691,017,337
Bonds payable	-	-
Including: Preferred shares	-	-
representative bonds	-	-
Leases liabilities	148,475,651	151,300,063
Long-term payables	47,419,833	76,236,879
Long-term employee benefits payable	-	-
Estimated liabilities	-	-
Deferred income	18,206,515	8,430,307
Deferred tax liabilities	40,820,058	40,313,059
Other non-current liabilities	-	-
	<hr/>	<hr/>
Total non-current liabilities	1,001,875,015	967,297,645
	<hr/> <hr/>	<hr/> <hr/>
Total liabilities	1,713,937,473	1,661,651,470
	<hr/> <hr/>	<hr/> <hr/>
Shareholders' equity:		
Share capital	72,358,900	72,670,000
Other instruments	-	-
Including: Preferred shares	-	-
representative bonds	-	-
Capital surplus	760,645,327	790,024,238
Less: Treasury stock	47,815,625	22,366,849
Other comprehensive income	-	-
Special reserves	-	-
Surplus reserves	38,399,577	38,399,577
Provisions for guarantees	-	-
Retained earnings	364,230,300	344,285,828
Total attributable to shareholders of the parent company	1,187,818,478	1,223,012,795
Non-controlling interests	123,811,420	120,288,896
	<hr/>	<hr/>
Total shareholders' equity	1,311,629,898	1,343,301,691
	<hr/> <hr/>	<hr/> <hr/>
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	3,025,567,371	3,004,953,161
	<hr/> <hr/>	<hr/> <hr/>

12.2.3 Annual Consolidated Statements of Cash Flow

(Amounts in B. uan ure ss oth r s stat d j)

Items	For the year ended December 31,	
	2025	2024
I. Cash flows from operating activities		
Cash received from sales of goods or rendering of services	1,772,490,027	1,387,505,398
net increase in customer deposits and in bank deposits	-	-
net increase in borrowings from intra bank	-	-
net increase in payments from other financial institutions	-	-
Cash received from foreign insurance contract premiums	-	-
net cash received from insurance business	-	-
net increase in deposits and investments from portfolio	-	-
Cash received from interests, fees and commissions	-	-
net increase in payments from banks and other financial institutions	-	-
net increase in cash from purchases business	-	-
net cash received from securities brokerage services	-	-
fund of taxes and levies	-	-
Cash received from other operating activities	73,327,922	46,542,855
Sub-total of cash inflows of operating activities	1,845,817,950	1,434,048,253
Cash paid for goods and services	570,409,686	536,137,779
net increase in customer loans and advances	-	-
net increase in deposits with intra bank and other banks	-	-
Cash paid for compensation under foreign insurance contract	-	-
net increase in payments with banks and other financial institutions	-	-
Cash paid for interests, fees and commissions	-	-
Cash paid for portfolio dividends	-	-
Cash paid to and on behalf of employees	664,306,093	642,555,983
payments of taxes and surcharges	58,559,038	63,003,045
Cash paid from other operating activities	112,573,575	92,712,942
Sub-total of cash outflows of operating activities	1,405,848,392	1,334,409,749
Net cash flows from operating activities	439,969,558	99,638,504

Items	For the year ended December 31,	
	2025	2024
II. Cash flows from investing activities		
Cash received from disposal of investments	14,540,026	34,242,179
Cash received from returns on investments	12,086	.
Net cash received from disposal of fixed assets, intangible assets and other long-term assets	173,820	1,844,120
Net cash received from disposal of subsidiaries and other businesses	-	2,000,000
Cash received relating to other investing activities	13,000,000	.
Sub-total of cash inflows of investing activities	27,725,932	38,086,299
Cash paid to acquire fixed assets, intangible assets and other long-term assets	189,507,952	192,178,989
Cash paid to acquire investments	1,200,000	17,020,000
Net cash paid for acquisitions	-	.
Net cash paid to acquire subsidiaries and other businesses	27,901,903	.
Cash paid relating to other investing activities	13,029,193	942,428
Sub-total of cash outflows of investing activities	231,639,048	210,141,417
Net cash flows from investing activities	-203,913,116	-172,055,118
III. Cash flows from financing activities		
Cash received from capital contributions	14,000,000	7,210,500
Including: Cash received from capital contributions by non-controlling shareholders of subsidiaries	14,000,000	7,210,500
Cash received from borrowings	433,102,530	448,460,250
Cash received relating to other financing activities	850,000	60,000,000
Sub-total of cash inflows of financing activities	447,952,530	515,670,750
Cash payments of borrowings	400,626,910	367,013,827
Cash payments for distribution of dividends, profit or net settlements	74,417,907	74,654,124
Including: Cash payments for distribution of dividends and profit by subsidiaries to non-controlling shareholders	1,515,124	2,923,034
Cash paid relating to other financing activities	176,491,833	150,919,617
Sub-total of cash outflows of financing activities	651,536,650	592,587,568
Net cash flows from financing activities	-203,584,120	-76,916,818

Items	For the year ended December 31,	
	2025	2024
IV. Effect of foreign exchange rate changes on cash and cash equivalents	<u>-30,315</u>	<u>-157,162</u>
V. Net increase in cash and cash equivalents	32,442,007	-149,490,595
Add: Cash and cash equivalents at the beginning of the period	<u>255,232,744</u>	<u>404,723,339</u>
VI. Cash and cash equivalents at the end of the period	<u>287,674,751</u>	<u>255,232,744</u>

12.2.4 Consolidated Statement of Changes in Shareholders' Equity

(Amounts in B. Yuan unless otherwise stated)

Items	Other equity instruments				Amount for the current period							Non - controlling interests	Total owners' equity	
	Share capital	Preferred shares	Perpetual bonds	Others	Equity attributable to owners of the parent company									
					Capital reserve	Treasury stock	Less: comprehensive income	Other reserve	Surplus reserve	Provision for general risk	Retained earnings			Subtotal
I. Balance as at the end of the previous year	72,670,000	-	-	-	790,024,238	22,366,849	-	-	38,399,577	-	344,285,828	1,223,012,795	120,288,896	1,343,301,691
Plus: Change in accounting policies	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Correction of accounting errors in prior periods	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Business combinations under common control	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Others	-	-	-	-	-	-	-	-	-	-	-	-	-	-
II. Balance as at the beginning of the current year	72,670,000	-	-	-	790,024,238	22,366,849	-	-	38,399,577	-	344,285,828	1,223,012,795	120,288,896	1,343,301,691
III. Increase/decrease in the current period														
(I) Total comprehensive income	-311,100	-	-	-	-29,378,911	25,448,777	-	-	-	-	19,944,472	-35,194,316	3,522,524	-31,671,793
(II) Other contribution and capital increase														
1. Common stock contributed by investors	-311,100	-	-	-	1,564,386	25,448,777	-	-	-	-	-	-24,195,490	25,399,704	1,144,214
2. Capital reserved by holders of other equity instruments	-311,100	-	-	-	-2,939,299	25,448,777	-	-	-	-	-	-28,699,175	25,399,704	-3,359,471
3. Amounts of share-based payments recognized in the current period	-	-	-	-	-	-	-	-	-	-	-	-	-	-
4. Others	-	-	-	-	4,503,685	-	-	-	-	-	-	4,503,685	-	4,503,685

Items	Other equity instruments				Amount for the current period								Non - controlling interests	Total owners' equity
	Share capital	Preferred shares	Perpetual bonds	Others	Equity attributable to owners of the parent company				Surplus reserve	Provision for general risk	Retained earnings	Subtotal		
					Capital reserve	Treasury stock	Less: comprehensive income	Other Special reserve						

(III) D s5.021

kt 115

Other instruments		Amount for the previous period	
Share	Capital	Share	Capital
Preferred	Perpetual	Preferred	Perpetual
Shares	Bonds	Stock	Preferred
	Others	Reserve	

Items	Amount for the previous period													
	Other equity instruments				Equity attributable to owners of the parent company									
	Share capital	Preferred shares	Repurchase bonds	Others	Capital reserves	Reserve for future losses	Reserve for comprehensive income	Special reserves	Surplus reserves	Reserve for general risk	Retained earnings	Subtotal	Controlling interests	Total equity
(III) Distribution of profits											-33,280,590	-33,280,590	-2,891,517	-36,172,107
1. Withdrawal of surplus reserves														
2. Withdrawal of provisions for general risk														
3. Profit distributed to owners (or shareholders)											-33,280,590	-33,280,590	-2,891,517	-36,172,107
4. Others														
(IV) Internal transfer of owners' equity														
1. Conversion of capital reserves into paid-up capital (or share capital)														
2. Conversion of surplus reserves into paid-up capital (or share capital)														
3. Surplus reserves offsetting losses														
4. Transfer of changes in the defined benefit plan for defined earnings														
5. Transfer of other comprehensive income for defined earnings														
6. Others														
(V) Special reserves														
1. Withdrawal for the period														
2. Add for the period														
(VI) Others					-35,233,759							-35,233,759		-35,233,759
IV. Balance as at the end of the period	72,670,000				790,024,238	22,366,849			38,399,577		344,285,828	1,223,012,795	120,288,896	1,343,301,691

12.3 Notes to the Consolidated Annual Financial Information prepared in accordance with the China Accounting Standard for Business Enterprises

12.3.1 Accounts receivable

The aging analysis of accounts receivable is based on the following data as follows:

	December 31, 2025 RMB	December 31, 2024 RMB
Within 1 year	461,352,555	576,106,514
1-2 years	25,588,614	20,258,896
2-3 years	8,844,668	4,413,822
Over 3 years	7,368,906	4,766,339
Subtotal	<u>503,154,743</u>	<u>605,545,571</u>
Less: provisions for bad debts	40,215,173	33,732,614
Total	<u><u>462,939,570</u></u>	<u><u>571,812,957</u></u>

Accounts receivable shown by classification of bad debt provisions

	December 31, 2025				
	Balance of carrying amount		Provision for bad debts		Book value
	Amount	Proportion (%)	Amount	Percent of provision (%)	
Accounts receivable with provisions for bad debts on the individual basis	15,171,844	3.0	15,171,844	100.0	
Including: Amount due from patients	15,171,844	3.0	15,171,844	100.0	0.00
Accounts receivable with provisions for bad debts on the grouping basis	487,982,899	97.0	25,043,329	5.1	462,939,570
Including: Ordinary grouping	<u>487,982,899</u>	<u>97.0</u>	<u>25,043,329</u>	<u>5.1</u>	<u>462,939,570</u>
Total	<u><u>503,154,743</u></u>	<u><u>100.0</u></u>	<u><u>40,215,173</u></u>	<u><u>8.0</u></u>	<u><u>462,939,570</u></u>

	December 31, 2024				Book value Amount
	Balance of carrying amount	Provisions for bad debt reported on	Balance of carrying amount	Provisions for bad debt reported on	
	Amount	(%)	Amount	(%)	Amount
Accounts receivable with provisions for bad debts on the individual basis	12,375,106	2.0	12,337,791	99.7	37,315
Including: Amount due from patients	12,375,106	2.0	12,337,791	99.7	37,315
Accounts receivable with provisions for bad debts on the grouping basis	593,170,465	98.0	21,394,823	3.6	571,775,642
Including: Overdue debts grouping	593,170,465	98.0	21,394,823	3.6	571,775,642
Total	605,545,571	100.0	33,732,614	5.6	571,812,957

12.3.2 Accounts payable

The aging analysis of accounts payable is based on the following dates as follows:

	December 31, 2025 RMB	December 31, 2024 RMB
Within 1 year	156,277,715	127,861,415
1-2 years	2,848,067	3,124,362
2-3 years	1,229,010	751,142
Over 3 years	448,301	199,461
Total	160,803,092	131,936,380

12.3.3 Revenue and cost of sales

The analysis of revenue and cost of sales is as follows:

	For the year ended December 31, 2025		For the year ended December 31, 2024	
	Revenue	Cost	Revenue	Cost
Business	1,448,705,601	1,074,924,943	1,517,773,042	1,125,416,715
Other business	171,078,810	125,790,275	136,516,371	90,468,771
Total	1,619,784,411	1,200,715,218	1,654,289,413	1,215,885,486

Breakdown of revenue:

	For the year ended December 31,	
	2025	2024
Revenue from main businesses	1,448,705,601	1,517,773,042
Including: pharmaceutical sales	304,326,145	331,193,218
Treatments and general healthcare services	1,144,379,456	1,186,579,824
Revenue from other businesses	171,078,810	136,516,371
Including: Wholesale and retail sale of pharmaceuticals and equipment	107,370,317	90,137,875
Manufacturing	2,368,851	2,970,297
Distribution	2,577,689	595,122
Leasing of services	36,811,653	16,136,947
Others	21,950,300	26,676,130
Total	<u>1,619,784,411</u>	<u>1,654,289,413</u>

12.3.4 Credit impairment losses

	For the year ended December 31,	
	2025	2024
Losses on bad debts of accounts receivable	14,485,650	19,116,072
Losses on bad debts of other receivables	-7,900,776	7,338,926
Total	<u>6,584,873</u>	<u>26,454,998</u>

12.3.5 Earnings per Share

Basic earnings per Share

	For the year ended December 31,	
	2025	2024
Consolidated net profit attributable to the ordinary shareholders of the parent company	54,395,980	65,610,189
Weighted average number of outstanding ordinary Shares of the Company	71,953,133	74,278,583
Basic earnings per Share	0.76	0.88
Including: Basic earnings per Share from continuing operations	0.76	0.88
Basic earnings per Share from discontinued operations	-	-

D ut de arn ngs p r Shar

D ut de arn ngs p r Shar s ca cu at d b th conso da d n t prof t attr butab e to th ord nar B shar ho d rs of th par nt compan B (d ut dj) d v d d b th e gh t d av rag nu m b r of outstand ng ord nar B Shar s of th Compan B (d ut dj):

	For the year ended December 31,	
	2025	2024
Conso da d n t prof t attr butab e to th ord nar B shar ho d rs of th par nt compan B (d ut dj)	54,395,980	65,610,189
W gh t d av rag nu m b r of outstand ng ord nar B Shar s of th Compan B (d ut dj)	71,953,133	74,278,583
D ut de arn ngs p r Shar	0.76	0.88
Inc ud ng: D ut de arn ngs p r Shar from cont nu ng op rat ons	0.76	0.88
D ut de arn ngs p r Shar from d scont nu d op rat ons	-	.

12.3.6 Income tax expenses

Tab e of nco . ta e p ns s

	For the year ended December 31,	
	2025	2024
Cur nt nco . ta e p ns s	29,205,810	35,746,101
D f r d nco . ta e p ns s	3,409,292	-18,044,326
Total	<u>32,615,101</u>	<u>17,701,775</u>

Impact on total profit and income tax expense

	For the year ended December 31,	
	2025	2024
Total profit	69,219,025	68,099,487
Income tax expense calculated at the statutory rate	10,382,854	13,700,455
Impact of different tax rates applicable to subsidiaries	7,485,630	-43,611
Adjustment to impact of income tax of past periods	-1,844,266	1,468,471
Impact of non-taxable income	568,437	.
Impact of non-deductible costs, expense and losses	3,163,935	6,053,711
Impact of deductible losses of the deferred income tax assets unrecognized in the previous period	-7,294,445	-12,352,475
Impact of deductible temporary differences or deductible losses for which deferred income tax assets are not recognized in the current period	25,822,435	16,429,655
Addtional deduction of research and development expense	-4,497,890	-5,605,853
Impact of business combination involving entities not under common control	-1,171,588	-10,362
Others	-	-1,938,216
Income tax expense	32,615,101	17,701,775

12.3.7 Dividend

On March 23, 2026, the Board proposed a cash dividend of RMB3.2 (net use of tax) per 10 Shares to all Shareholders of the Company, based on the total share capital for the record date determined by the supermajority of the proposed distribution of profit for the year 2025 (including the number of Shares purchased but not yet canceled by the Company). As of the date of this announcement, the Company's total share capital is 72,358,900 Shares. After deducting 1,959,800 Shares purchased but not yet canceled by the Company, the total cash dividend proposed for distribution is provisionally RMB22,527,712 (net use of tax). The proposed dividend is subject to approval at the extraordinary general meeting.

On August 12, 2025, the Board proposed an interim dividend of RMB13,024,602 (net use of tax) to all Shareholders of the Company for the six-month period ended June 30, 2025, calculated on the basis of the total share capital of 72,358,900 Shares for the record date determined by the supermajority of the 2025 interim profit distribution plan. The proposed dividend was approved at the first extraordinary general meeting for the year 2025 of the Company on October 15, 2025.

On March 28, 2025, the Board proposed a final dividend of RMB3 (net use of tax) per 10 Shares to all Shareholders of the Company for the year ended December 31, 2024, totaling RMB21,801,000 (net use of tax), calculated on the basis of 72,670,000 Shares of the Company in issue as at December 31, 2024. The proposed dividend was approved at the annual general meeting for the year 2024 of the Company held on June 30, 2025.

13 DEFINITIONS

- “Annual general meeting” – the annual general meeting of the Company for the year 2025 to be convened during the course
- “Audit Committee” – the audit committee of the Board
- “Beijing Yining Hospital” – Beijing Yining Hospital Co., Ltd. (北京怡寧醫院有限公司), a company established in the PRC and established on August 17, 2015, one of the Company's indirect non-controlling subsidiaries
- “Board” – the board of directors of the Company
- “Company” or “Wanhou Angning Hospital” – Wanhou Angning Hospital Co., Ltd., a listed stock and established company established under the laws of the PRC, the Shares of which are listed on the Shanghai Stock Exchange of Hong Kong Limited (Stock Code: 2120)
- “Code” – the Corporate Governance Code contained in Appendix C1 to the Hong Kong Listing Rules

“Director(s)”	the director(s) of the Company
“Domestic Share (s)”	ordinary Share (s) in the share capital of the Company, with a nominal value of RMB1.00 each, which are subscribed for and paid up in RMB and are unlisted Shares which are currently not listed or traded on any stock exchange
“Group” or “e” or “our”	the Company and its subsidiaries
“Share (s)”	ordinary listed foreign new listed ordinary Share (s) in the ordinary share capital of the Company, with a nominal value of RMB1.00 each, listed on the Shanghai Stock Exchange of Hong Kong Limited
“\$” or “D”	the respective currencies of Hong Kong
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“Hong Kong Listing Rules”	the Listing Rules governing the listing of Securities on the Stock Exchange of Hong Kong Limited as amended, supplemented or otherwise modified from time to time
“Hong Kong Stock Exchange”	The Stock Exchange of Hong Kong Limited
“Huainan Angning Hospital”	Huainan Angning Hospital Co., Ltd. (淮南康寧醫院有限公司), a company established in the PRC, which was established on September 22, 2017, one of the Company's indirect non-holding Board subsidiaries
“Jin Yun Shunng Hospital”	Jin Yun Shunng Hospital Co., Ltd. (縉雲舒寧醫院有限公司), a company established in the PRC, which was established on February 15, 2019, one of the Company's non-holding Board subsidiaries
“Longquan Angning Hospital”	Longquan Angning Hospital Co., Ltd. (龍泉康寧醫院有限公司), a company established in the PRC, which was established on February 6, 2023, one of the Company's indirect holding Board subsidiaries
“Wenzhou Yichang Hospital”	Wenzhou Yichang Hospital Co., Ltd. (溫州鹿城怡寧醫院有限公司), a company established in the PRC, which was established on April 2, 2020, one of the Company's direct non-holding Board subsidiaries
“Taizhou Cening Hospital”	Taizhou Yuchao Cening Hospital Co., Ltd. (台州市路橋慈寧醫院有限公司), previously known as Taizhou Yuchao Hospital Co., Ltd. (台州市路橋怡寧醫院有限公司), a company established in the PRC, which was established on December 12, 2016, one of the Company's indirect non-holding Board subsidiaries

“ ng Pang Change ng
n ng osp ta -”

“ n ng s Bcho og B
Int ra t osp ta -

n ng s Bcho og B Int ra t osp ta (W n hou) Co.,
td. (怡寧心理互聯網醫院(溫州)有限公司), a compan
e stab sh d n th C th ud ab tBon arch 10,
2020, on of th Compan's nd ct ho B o n d
subs d ae s

“ ong a angn ng osp ta -”

ong a angn ng osp ta Co., td. (永嘉康寧醫院有
限公司), a compan e stab sh d n th C th ud ab tBon
De ub r 12, 2012, on of th Compan's
ho B o n d subs d ae s

“ % -”

p re ntag rat o

B BOrd r of th Board
Wenzhou Kangning Hospital Co., Ltd.
GUAN Weili
Cha ruan

Zh ang, th C
arch 23, 2026

As of th dat of th s announ e nt, th Compan's e e cut e D e ctors ar r. A W , s.
WA an Ba and r. WA Jan; th non e e cut e D e ctors ar r. QI ao and r. I
Changhao; and th nd p nd nt non e e cut e D e ctors ar s. Z O W ntang, s. JI ng
and r. C A Sa e ung ugo.